Nuclear Science and Techniques

《核技术》(英文版) ISSN 1001-8042 CN 31-1559/TL     2018 Impact factor 0.961

Nuclear Science and Techniques ›› 2004, Vol. 15 ›› Issue (2): 102

• RADIOCHEMISTRY, RADIOPHARMACEUTICALS AND NUCLEAR MEDICIN • Previous Articles     Next Articles

Preparation and bio-distribution of 153Sm-HEDTMP as a radiopharmaceutical for bone metastases

JIANG Shu-Bin,1 LUO Shun-Zhong,1 HU Shu,2 DENG Hou-Fu,2 BIN Wen-Zeng,1 WANG Wen-Jin,1 WEI Hong-Yuan,1 LEI Yong2   

  1. 1Institute of Nuclear Physics and Chemistry, the China Academy of Engineering Physics, Mianyang 621900;
    2Department of Nuclear Medicine of First University Hospital, West China Medicine Center, Sichuan University, Chengdu 610041
PDF ShareIt Export Citation
JIANG Shu-Bin, LUO Shun-Zhong, HU Shu, DENG Hou-Fu, BIN Wen-Zeng, WANG Wen-Jin, WEI Hong-Yuan, LEI Yong. Preparation and bio-distribution of 153Sm-HEDTMP as a radiopharmaceutical for bone metastases.Nuclear Science and Techniques, 2004, 15(2): 102

Abstract: HEDTMP (N-(2-hydroxyethyl) ethlenediamine-1,1,2-tri(methylene phosphonic acid)) was labeled with 153Sm. The formation condition, stability, rabbit bone imaging and mouse bio-distribution of 153Sm -HEDTMP were investigated. The results showed that weak basic media and high ligand’s concentration were favorable to form 153Sm-HEDTMP, and neutral or weak basic media increase the stability of 153Sm-HEDTMP. And the higher the concentration of HEDTMP was, the more stable the labeling complex was. Bio-distribution study indicated the uptake of 153Sm-HEDTMP in skeleton was high ((25.68±1.22)ID%/g bone at 3 h post injection and (16.56±1.01)ID%/g bone at 48 h post injection), while the non-target tissue uptake and retention were relatively low, so 153Sm-HEDTMP is a promising bone tumor therapeutic agent

Key words: Samarium-153, HEDTMP, Bone tumor, Bio-distribution